{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:13:43Z","timestamp":1789517623155,"version":"build-2803163510"},"reference-count":181,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Patients with mental disorders have an increased risk to develop cardiovascular disease (CVD), and CVD are frequently comorbid with especially adjustment, anxiety and depressive disorders. Therefore, clinicians need to be aware of effective and safe psychological and pharmacological treatment strategies for patients with comorbid CVD and mental disorders. Cognitive behavioral therapy and third-wave of cognitive-behavioral therapy are effective for patients with CVD and mental disorders. Internet-based psychological treatments may also be considered. In more severe cases, psychopharmacological drugs are frequently used. Although generally well tolerated and efficacious, drug- and dose-dependent side effects require consideration. Among antidepressants, selective serotonin reuptake inhibitors, selective serotonin and noradrenalin reuptake inhibitors, and newer antidepressants, such as mirtazapine, bupropion, agomelatine, and vortioxetine, can be considered, while tricyclic antidepressants should be avoided due to their cardiac side effects. Mood stabilizers have been associated with arrhythmias, and some first- and second-generation antipsychotics can increase QTc and metabolic side effects, although substantial differences exist between drugs. Benzodiazepines are generally safe in patients with CVD when administered short-term, and may mitigate symptoms of acute coronary syndrome. Laboratory and ECG monitoring is always recommended in psychopharmacological drug-treated patients with CVD. Presence of a heart disease should not exclude patients from necessary interventions, but may require careful risk-benefit evaluations. Effectively and safely addressing mental disorders in patients with CVD helps to improve both conditions. Since CVD increase the risk for mental disorders and vice versa, care providers need to screen for these common comorbidities to comprehensively address the patients\u2019 needs.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.831359","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T01:59:11Z","timestamp":1647395951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Psychological and Psychopharmacological Interventions in Psychocardiology"],"prefix":"10.3389","volume":"13","author":[{"given":"Kai G.","family":"Kahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Stapel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/eurheartj\/eht462","article-title":"Depression and cardiovascular disease: a clinical review.","volume":"35","author":"Hare","year":"2014","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/CRD.0b013e31820e8106","article-title":"Depression and cardiac disease: a review.","volume":"19","author":"Celano","year":"2011","journal-title":"Cardiol Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s0006-3223(03)00587-0","article-title":"Epidemiology of comorbid coronary artery disease and depression.","volume":"54","author":"Rudisch","year":"2003","journal-title":"Biol Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.jacc.2003.07.007","article-title":"Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction.","volume":"42","author":"Strik","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/01.psy.0000233233.48738.22","article-title":"Assessment and treatment of depression in patients with cardiovascular disease: national heart, lung, and blood institute working group report.","volume":"32","author":"Davidson","year":"2006","journal-title":"Ann Behav Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/01.HCR.0000265036.24157.e7","article-title":"Prevalence of anxiety disorders in men and women with established coronary heart disease.","volume":"27","author":"Todaro","year":"2007","journal-title":"J Cardiopulm Rehabil Prev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/hrt.2004.059451","article-title":"Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months.","volume":"92","author":"de Jonge","year":"2006","journal-title":"Heart."},{"key":"B9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1176\/appi.psy.46.4.355","article-title":"Depression following acute myocardial infarction: a prospective relationship with ongoing health and function.","volume":"46","author":"Fauerbach","year":"2005","journal-title":"Psychosomatics."},{"key":"B10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s0006-3223(03)00111-2","article-title":"Depression, mortality, and medical morbidity in patients with coronary heart disease.","volume":"54","author":"Carney","year":"2003","journal-title":"Biol Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1001\/jama.284.20.2606","article-title":"Smoking and mental illness: a population-based prevalence study.","volume":"284","author":"Lasser","year":"2000","journal-title":"JAMA."},{"key":"B12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.schres.2018.03.016","article-title":"Dietary patterns and physical activity in people with schizophrenia and increased waist circumference.","volume":"199","author":"Jakobsen","year":"2018","journal-title":"Schizophr Res."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005977","article-title":"Association of outpatient practice-level socioeconomic disadvantage with quality of care and outcomes among older adults with coronary artery disease: implications for value-based payment.","volume":"13","author":"Wadhera","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0706743718762097","article-title":"Social determinants of health and preclinical glycemic control in newly diagnosed first-episode psychosis patients.","volume":"63","author":"Veru-Lesmes","year":"2018","journal-title":"Can J Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.schres.2019.12.019","article-title":"Socioeconomic deprivation and blood lipids in first-episode psychosis patients with minimal antipsychotic exposure: implications for cardiovascular risk.","volume":"216","author":"Veru-Lesmes","year":"2020","journal-title":"Schizophr Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/7854_2016_28","article-title":"Inflammation-associated co-morbidity between depression and cardiovascular disease.","volume":"31","author":"Halaris","year":"2017","journal-title":"Curr Top Behav Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1365-2796.2000.00603.x","article-title":"The hypothalamic\u2013pituitary\u2013adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke.","volume":"247","author":"Rosmond","year":"2000","journal-title":"J Intern Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1586\/erc.09.78","article-title":"Depression and the cardiovascular system: increasing evidence of a link and therapeutic implications.","volume":"7","author":"Marano","year":"2009","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.","volume":"5","author":"Ringen","year":"2014","journal-title":"Front Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1192\/bjp.bp.111.094532","article-title":"Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis.","volume":"201","author":"Mitchell","year":"2012","journal-title":"Br J Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jad.2017.09.002","article-title":"Hypertension risk and clinical care in patients with bipolar disorder or schizophrenia; a systematic review and meta-analysis.","volume":"225","author":"Ayerbe","year":"2018","journal-title":"J Affect Disord."},{"key":"B23","author":"Schneider","year":"2017","journal-title":"S3-Leitlinie\/Nationale VersorgungsLeitlinie Unipolare Depression."},{"key":"B24","author":"Bandelow","year":"2021","journal-title":"Deutsche S3-Leitlinie Behandlung von Angstst\u00f6rungen, Version 2."},{"key":"B25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2174\/1381612043383872","article-title":"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?","volume":"10","author":"Pacher","year":"2004","journal-title":"Curr Pharm Des."},{"key":"B27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3724\/SP.J.1263.2011.00243","article-title":"Cardiologic side effects of psychotropic drugs.","volume":"8","author":"Marano","year":"2011","journal-title":"J Geriatr Cardiol."},{"key":"B28","year":"","journal-title":"Practice Guideline for the Treatment of Patients with Major Depressive Disorder."},{"key":"B29","year":"2009","journal-title":"Depression in Adults: Recognition and Management."},{"key":"B30","year":"2011","journal-title":"Generalised Anxiety Disorder and Panic Disorder in Adults: Management."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0269881109348176","article-title":"Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis.","volume":"24","author":"Mazza","year":"2010","journal-title":"J Psychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.4088\/JCP.13r08672","article-title":"Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.","volume":"75","author":"Beach","year":"2014","journal-title":"J Clin Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/bcp.12681","article-title":"Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam study.","volume":"80","author":"Maljuric","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160768","article-title":"Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study.","volume":"11","author":"Qirjazi","year":"2016","journal-title":"PLoS One."},{"key":"B35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/00008571-200010000-00003","article-title":"Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin.","volume":"10","author":"Haritos","year":"2000","journal-title":"Pharmacogenetics."},{"key":"B36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00003088-200443060-00002","article-title":"Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.","volume":"43","author":"Crone","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.euroneuro.2013.05.011","article-title":"The cardiovascular safety profile of escitalopram.","volume":"23","author":"Thase","year":"2013","journal-title":"Eur Neuropsychopharmacol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f288","article-title":"QT interval and antidepressant use: a cross sectional study of electronic health records.","volume":"346","author":"Castro","year":"2013","journal-title":"BMJ."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1177\/1060028013501994","article-title":"A comparison of the risk of QT prolongation among SSRIs.","volume":"47","author":"Funk","year":"2013","journal-title":"Ann Pharmacother."},{"key":"B40","year":"2011","journal-title":"Pharmacovigilance Working Party (PhVWP)."},{"key":"B41","year":"2012","journal-title":"FDA Drug Safety Communication: Revised Recommendations for Celexa (Citalopram Hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with High Doses."},{"key":"B42","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.psym.2014.01.010","article-title":"Antidepressants and the risk of hyponatremia: a class-by-class review of literature.","volume":"55","author":"De Picker","year":"2014","journal-title":"Psychosomatics."},{"key":"B43","first-page":"519","article-title":"Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports.","volume":"155","author":"Liu","year":"1996","journal-title":"CMAJ."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15280","article-title":"A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database.","volume":"15","author":"Coupland","year":"2011","journal-title":"Health Technol Assess."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4551","article-title":"Antidepressant use and risk of adverse outcomes in older people: population based cohort study.","volume":"343","author":"Coupland","year":"2011","journal-title":"BMJ."},{"key":"B46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1017\/S1461145711001192","article-title":"Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme.","volume":"15","author":"Letmaier","year":"2012","journal-title":"Int J Neuropsychopharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1055\/s-2004-815509","article-title":"Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.","author":"Degner","year":"2004","journal-title":"Pharmacopsychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/gps.591","article-title":"Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit.","volume":"17","author":"Kirby","year":"2002","journal-title":"Int J Geriatr Psychiatry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/s0895-4356(96)00385-x","article-title":"Risk of syncope in the elderly and consumption of drugs: a case-control study.","volume":"50","author":"Cherin","year":"1997","journal-title":"J Clin Epidemiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"936","DOI":"10.4088\/jcp.v63n1012","article-title":"Risk factors for falls during treatment of late-life depression.","volume":"63","author":"Joo","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"B51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002512-200926050-00002","article-title":"Antidepressants and falls in the elderly.","volume":"26","author":"Darowski","year":"2009","journal-title":"Drugs Aging."},{"key":"B52","first-page":"4","article-title":"Adverse reactions of antidepressants in elderly patients.","author":"Pollock","year":"1999","journal-title":"J Clin Psychiatry."},{"key":"B53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/STROKEAHA.115.011574","article-title":"Antidepressant use is associated with an increased risk of developing microbleeds.","volume":"47","author":"Akoudad","year":"2016","journal-title":"Stroke."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.4088\/JCP.09r05786blu","article-title":"Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms.","volume":"71","author":"Andrade","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002022","article-title":"Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan.","volume":"94","author":"Cheng","year":"2015","journal-title":"Medicine (Baltimore)."},{"key":"B56","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.amjcard.2014.05.037","article-title":"Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin.","volume":"114","author":"Quinn","year":"2014","journal-title":"Am J Cardiol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h3517","article-title":"Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study.","volume":"351","author":"Shin","year":"2015","journal-title":"BMJ."},{"key":"B58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.vph.2017.07.004","article-title":"Effects of psychopharmacological treatment with antidepressants on the vascular system.","author":"Kahl","year":"2017","journal-title":"Vascul Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2018-0054","article-title":"Direct and indirect effects of psychopharmacological treatment on the cardiovascular system.","volume":"36","author":"Kahl","year":"2018","journal-title":"Horm Mol Biol Clin Investig."},{"key":"B60","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1017\/s1092852900019726","article-title":"SNRIs: the pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectr."},{"key":"B61","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1503\/jpn.140217","article-title":"Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis.","volume":"41","author":"Alvares","year":"2016","journal-title":"J Psychiatry Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00004850-199503002-00004","article-title":"Safety and tolerance profile of venlafaxine.","author":"Danjou","year":"1995","journal-title":"Int Clin Psychopharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"54S","DOI":"10.1097\/00004714-199606002-00011","article-title":"The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database.","volume":"16","author":"Rudolph","year":"1996","journal-title":"J Clin Psychopharmacol."},{"key":"B64","first-page":"574","article-title":"Cardiovascular safety in depressed patients: focus on venlafaxine.","volume":"56","author":"Feighner","year":"1995","journal-title":"J Clin Psychiatry."},{"key":"B65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1185\/030079906X162719","article-title":"A retrospective pooled analysis of duloxetine safety in 23 983 subjects.","volume":"23","author":"Gahimer","year":"2007","journal-title":"Curr Med Res Opin."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1177\/1060028014550645","article-title":"Risk of QT\/QTc prolongation among newer non-SSRI antidepressants.","volume":"48","author":"Jasiak","year":"2014","journal-title":"Ann Pharmacother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management.","volume":"149","author":"Tisdale","year":"2016","journal-title":"Can Pharm J (Ott)."},{"key":"B68","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1345\/aph.1P391","article-title":"Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French health data.","volume":"45","author":"Mease","year":"2011","journal-title":"Ann Pharmacother."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1517\/14656566.2014.960842","article-title":"A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.","volume":"15","author":"Deardorff","year":"2014","journal-title":"Expert Opin Pharmacother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/NDT.S54710","article-title":"Levomilnacipran for the treatment of major depressive disorder: a review.","volume":"11","author":"Asnis","year":"2015","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011200","article-title":"Antidepressants and the risk of hyponatremia: a Danish register-based population study.","volume":"6","author":"Leth-M\u00f8ller","year":"2016","journal-title":"BMJ Open."},{"key":"B72","first-page":"256","article-title":"Antidepressants: their effects on cardiac channels, QT prolongation and torsade de pointes.","volume":"7","author":"Sala","year":"2006","journal-title":"Curr Opin Investig Drugs."},{"key":"B73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2165\/00139709-200524030-00013","article-title":"Tricyclic antidepressant poisoning : cardiovascular toxicity.","volume":"24","author":"Thanacoody","year":"2005","journal-title":"Toxicol Rev."},{"key":"B74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.7182\/prtr.14.2.40w9186064m78653","article-title":"Use of antidepressant drugs in transplant recipients.","volume":"14","author":"Kim","year":"2004","journal-title":"Prog Transplant."},{"key":"B75","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/JCP.0b013e31829c970e","article-title":"Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study.","volume":"33","author":"Lee","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1586\/14737175.2014.908709","article-title":"Cardiovascular adverse effects of newer antidepressants.","volume":"14","author":"Mago","year":"2014","journal-title":"Expert Rev Neurother."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.euroneuro.2016.08.012","article-title":"H1-histamine receptor affinity predicts weight gain with antidepressants.","volume":"26","author":"Salvi","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/PSY.0b013e31814b260d","article-title":"Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.","volume":"69","author":"Honig","year":"2007","journal-title":"Psychosom Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1871527315666161025140111","article-title":"Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine.","volume":"16","author":"Orsolini","year":"2017","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2017.11.056","article-title":"Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis.","volume":"228","author":"Wagner","year":"2018","journal-title":"J Affect Disord."},{"key":"B81","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jad.2017.06.034","article-title":"Treatment of neurocognitive symptoms in unipolar depression: a systematic review and future perspectives.","volume":"221","author":"Salagre","year":"2017","journal-title":"J Affect Disord."},{"key":"B82","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/10401239409148989","article-title":"The cardiovascular effects of bupropion and nortriptyline in depressed outpatients.","volume":"6","author":"Kiev","year":"1994","journal-title":"Ann Clin Psychiatry."},{"key":"B83","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1176\/ajp.148.4.512","article-title":"Cardiovascular effects of bupropion in depressed patients with heart disease.","volume":"148","author":"Roose","year":"1991","journal-title":"Am J Psychiatry."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.amjmed.2006.04.024","article-title":"Bupropion for smokers hospitalized with acute cardiovascular disease.","volume":"119","author":"Rigotti","year":"2006","journal-title":"Am J Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5694\/j.1326-5377.2003.tb05064.x","article-title":"Bupropion poisoning: a case series.","volume":"178","author":"Balit","year":"2003","journal-title":"Med J Aust."},{"key":"B86","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1176\/appi.focus.18306","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"18","author":"Huhn","year":"2020","journal-title":"Focus (Am Psychiatr Publ)."},{"key":"B87","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry."},{"key":"B88","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1038\/s41380-020-00946-6","article-title":"Mood stabilizers and\/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.","volume":"26","author":"Kishi","year":"2021","journal-title":"Mol Psychiatry."},{"key":"B89","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/bdi.13053","article-title":"Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: a systematic review and meta-analysis of randomized, placebo-controlled trials.","volume":"23","author":"Kishi","year":"2021","journal-title":"Bipolar Disord."},{"key":"B90","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.euroneuro.2021.08.264","article-title":"Preventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials.","volume":"54","author":"Nestsiarovich","year":"2022","journal-title":"Eur Neuropsychopharmacol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis.","volume":"302","author":"Nunez","year":"2022","journal-title":"J Affect Disord."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2015.00297","article-title":"Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management.","volume":"9","author":"Ventriglio","year":"2015","journal-title":"Front Neurosci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The lancet psychiatry commission: a blueprint for protecting physical health in people with mental illness.","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications.","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics."},{"key":"B96","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40263-014-0196-9","article-title":"QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.","volume":"28","author":"Hasnain","year":"2014","journal-title":"CNS Drugs."},{"key":"B97","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3238\/arztebl.2011.0687","article-title":"QTc prolongation by psychotropic drugs and the risk of torsade de pointes.","volume":"108","author":"Wenzel-Seifert","year":"2011","journal-title":"Dtsch Arztebl Int."},{"key":"B98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/JCP.0b013e318191c6a8","article-title":"Psychotropic drugs associated with corrected QT interval prolongation.","volume":"29","author":"van Noord","year":"2009","journal-title":"J Clin Psychopharmacol."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1097\/01720610-201302000-00002","article-title":"QT prolongation: a critical adverse effect of some medications.","volume":"26","author":"DeDea","year":"2013","journal-title":"JAAPA."},{"key":"B100","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","article-title":"Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.","volume":"28","author":"Fusar-Poli","year":"2013","journal-title":"Int Clin Psychopharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.pra.0000450319.21859.6d","article-title":"QTc prolongation with antipsychotics: is routine ECG monitoring recommended?","volume":"20","author":"Shah","year":"2014","journal-title":"J Psychiatr Pract."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.12669\/pjms.315.8998","article-title":"Antipsychotic medication and QT prolongation.","volume":"31","author":"Chohan","year":"2015","journal-title":"Pak J Med Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/070674371506000503","article-title":"Antipsychotic polypharmacy and corrected QT interval: a systematic review.","volume":"60","author":"Takeuchi","year":"2015","journal-title":"Can J Psychiatry."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001568","article-title":"Antipsychotic drugs and the risk of ventricular arrhythmia and\/or sudden cardiac death: a nation-wide case-crossover study.","volume":"4","author":"Wu","year":"2015","journal-title":"J Am Heart Assoc."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148212","article-title":"Antipsychotic dose mediates the association between polypharmacy and corrected QT interval.","volume":"11","author":"Barbui","year":"2016","journal-title":"PLoS One."},{"key":"B106","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/hup.2540","article-title":"First-generation antipsychotics and QTc: any role for mediating variables?","volume":"31","author":"Carra","year":"2016","journal-title":"Hum Psychopharmacol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1517\/14740338.2016.1161021","article-title":"Cardiovascular safety of antipsychotics: a clinical overview.","volume":"15","author":"Polcwiartek","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"B108","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/0269881116684337","article-title":"Psychotropic drugs and ventricular repolarisation: the effects on QT interval, T-peak to T-end interval and QT dispersion.","volume":"31","author":"Acciavatti","year":"2017","journal-title":"J Psychopharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1254\/jphs.qt-c13","article-title":"QT PRODACT: usability of miniature pigs in safety pharmacology studies: assessment for drug-induced QT interval prolongation.","volume":"99","author":"Kano","year":"2005","journal-title":"J Pharmacol Sci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death.","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","article-title":"Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.","volume":"62","author":"Haddad","year":"2002","journal-title":"Drugs."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes.","volume":"89","author":"Yap","year":"2003","journal-title":"Heart."},{"key":"B113","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-0447.1991.tb01421.x","article-title":"A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland.","volume":"84","author":"Mehtonen","year":"1991","journal-title":"Acta Psychiatr Scand."},{"key":"B114","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.","volume":"24","author":"Harrigan","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JCP.0b013e31827c0314","article-title":"A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and\/or CYP3A4 and a comparison to quetiapine and ziprasidone.","volume":"33","author":"Potkin","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","article-title":"Risk factors for QTc-prolongation: systematic review of the evidence.","volume":"39","author":"Vandael","year":"2017","journal-title":"Int J Clin Pharm."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1001\/archinte.165.22.2677","article-title":"Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents.","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(00)02784-7","article-title":"Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study.","volume":"356","author":"Zornberg","year":"2000","journal-title":"Lancet."},{"key":"B119","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1176\/jnp.2009.21.3.343a","article-title":"Cerebral venous sinus thrombosis may be associated with clozapine.","volume":"21","author":"Werring","year":"2009","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1192\/bjp.179.1.63","article-title":"Antipsychotic medication and venous thrombosis.","volume":"179","author":"Thomassen","year":"2001","journal-title":"Br J Psychiatry."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1742-1241.2010.02435.x","article-title":"The importance of venous thromboembolism \u2013 a physical consequence of psychiatric treatments.","volume":"64","author":"Stansby","year":"2010","journal-title":"Int J Clin Pract."},{"key":"B122","first-page":"175","article-title":"Thrombotic complications of treatment with antipsychotic drugs.","volume":"104","author":"Shulman","year":"2013","journal-title":"Minerva Med."},{"key":"B123","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0037-1613188","article-title":"Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism.","volume":"88","author":"Ray","year":"2002","journal-title":"Thromb Haemost."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study.","volume":"341","author":"Parker","year":"2010","journal-title":"BMJ."},{"key":"B125","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-2007-979493","article-title":"Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy.","volume":"30","author":"Pantel","year":"1997","journal-title":"Pharmacopsychiatry."},{"key":"B126","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.pnpbp.2004.08.010","article-title":"Left atrial thrombosis associated with antipsychotic drugs.","volume":"29","author":"Numata","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B127","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1440-1819.2004.01284.x","article-title":"Two cases of deep vein thrombosis associated with antipsychotic drug use.","volume":"58","author":"Matsumoto","year":"2004","journal-title":"Psychiatry Clin Neurosci."},{"key":"B128","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1440-1819.2007.01773.x","article-title":"Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients.","volume":"62","author":"Maly","year":"2008","journal-title":"Psychiatry Clin Neurosci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2165\/00023210-200216110-00005","article-title":"Antipsychotic-induced venous thromboembolism: a review of the evidence.","volume":"16","author":"Hagg","year":"2002","journal-title":"CNS Drugs."},{"key":"B130","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.yic.0000085241.99018.30","article-title":"Olanzapine and venous thromboembolism.","volume":"18","author":"H\u00e4gg","year":"2003","journal-title":"Int Clin Psychopharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0140-6736(05)74504-9","article-title":"Antipsychotic drugs and venous thromboembolism.","volume":"356","author":"Knudson","year":"2000","journal-title":"Lancet."},{"key":"B132","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-61753-3","author":"Benkert","year":"2021","journal-title":"Kompendium der Psychiatrischen Pharmakotherapie."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients.","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"B134","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis.","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"B135","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1192\/bjp.bp.117.200907","article-title":"Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis.","volume":"211","author":"Pillinger","year":"2017","journal-title":"Br J Psychiatry."},{"key":"B136","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis.","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull."},{"key":"B137","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2165\/11591710-000000000-00000","article-title":"Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.","volume":"25","author":"Gugger","year":"2011","journal-title":"CNS Drugs."},{"key":"B138","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/cap.2011.0024","article-title":"Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study.","volume":"21","author":"Correll","year":"2011","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"B140","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","year":"2004","journal-title":"Diabetes Care."},{"key":"B141","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/HRP.0000000000000190","article-title":"Prescription benzodiazepine use among older adults: a critical review.","volume":"26","author":"Gerlach","year":"2018","journal-title":"Harv Rev Psychiatry."},{"key":"B142","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40266-018-0569-8","article-title":"Insomnia in elderly patients: recommendations for pharmacological management.","volume":"35","author":"Abad","year":"2018","journal-title":"Drugs Aging."},{"key":"B143","first-page":"92","article-title":"Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting.","volume":"29","author":"Correll","year":"2017","journal-title":"Ann Clin Psychiatry."},{"key":"B144","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.mcna.2021.08.012","article-title":"Benzodiazepines and related sedatives.","volume":"106","author":"Peng","year":"2022","journal-title":"Med Clin North Am."},{"key":"B145","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1684\/pnv.2021.0982","article-title":"Paradoxical reactions to benzodiazepines in the elderly.","volume":"35","author":"Champion","year":"2021","journal-title":"Geriatr Psychol Neuropsychiatr Vieil."},{"key":"B146","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/CRD.0b013e3181867fe3","article-title":"An integrated approach to the diagnosis and treatment of anxiety within the practice of cardiology.","volume":"17","author":"Janeway","year":"2009","journal-title":"Cardiol Rev."},{"key":"B147","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2014.05.918","article-title":"Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction: a national wide assessment.","volume":"235","author":"Wu","year":"2014","journal-title":"Atherosclerosis."},{"key":"B148","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5271\/sjweh.2319","article-title":"Psychological stress and cardiovascular diseases.","volume":"10","author":"Wheatley","year":"1984","journal-title":"Scand J Work Environ Health."},{"key":"B149","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1017\/S1092852916000523","article-title":"Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.","volume":"21","author":"Solmi","year":"2016","journal-title":"CNS Spectr."},{"key":"B150","first-page":"355","article-title":"Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder.","volume":"28","author":"Baethge","year":"2003","journal-title":"J Psychiatry Neurosci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amjmed.2005.11.003","article-title":"Lithium: clinical considerations in internal medicine.","volume":"119","author":"Freeman","year":"2006","journal-title":"Am J Med."},{"key":"B152","first-page":"p. 1043","article-title":"Psychopharmacology in the treatment of patients with cardiovascular disease.","author":"Beach","year":"2016","journal-title":"Handbook of Psychocardiology."},{"key":"B153","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"Valproic acid monotherapy in pregnancy and major congenital malformations.","volume":"362","author":"Jentink","year":"2010","journal-title":"N Engl J Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2019.04.019","article-title":"Valproic acid-induced coagulopathy.","volume":"98","author":"Kumar","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B155","first-page":"15","article-title":"Valproic acid and thrombocytopenia: cross-sectional study.","volume":"7","author":"Ko","year":"2001","journal-title":"Hong Kong Med J."},{"key":"B156","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/MBC.0b013e3282f3f9ec","article-title":"High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study.","volume":"19","author":"Koenig","year":"2008","journal-title":"Blood Coagul Fibrinolysis."},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.927830","article-title":"Valproic acid-induced thrombocytopenia-related spontaneous systemic bleeding.","volume":"21","author":"Johnston","year":"2020","journal-title":"Am J Case Rep."},{"key":"B158","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/pde.14598","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: a 25-year retrospective study at a single tertiary care center.","volume":"38","author":"Gleghorn","year":"2021","journal-title":"Pediatr Dermatol."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00711","article-title":"Effects of cognitive behavioral therapy-based intervention on improving glycaemic, psychological, and physiological outcomes in adult patients with diabetes mellitus: a meta-analysis of randomized controlled trials.","volume":"11","author":"Yang","year":"2020","journal-title":"Front Psychiatry."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.5498\/wjp.v11.i11.1147","article-title":"Effectiveness of cognitive behavioral therapy-based interventions on health outcomes in patients with coronary heart disease: a meta-analysis.","volume":"11","author":"Li","year":"2021","journal-title":"World J Psychiatry."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2021.101477","article-title":"The efficacy of cognitive behavioral therapy-based interventions on patients with hypertension: a systematic review and meta-analysis.","volume":"23","author":"Li","year":"2021","journal-title":"Prev Med Rep."},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6552246","article-title":"Effects of cognitive behavioral therapy on pain and sleep in adults with traumatic brain injury: a systematic review and meta-analysis.","volume":"2021","author":"Li","year":"2021","journal-title":"Neural Plast."},{"key":"B163","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/10503307.2014.1002440","article-title":"Cognitive behavioral therapy: current status and future research directions.","volume":"25","author":"McMain","year":"2015","journal-title":"Psychother Res."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081554","article-title":"Depression associated with reduced heart rate variability predicts outcome in adult congenital heart disease.","volume":"10","author":"Westhoff-Bleck","year":"2021","journal-title":"J Clin Med."},{"key":"B165","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1002\/ehf2.12967","article-title":"Assessment of major mental disorders in a German peripartum cardiomyopathy cohort.","volume":"7","author":"Pfeffer","year":"2020","journal-title":"ESC Heart Fail."},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.667602","article-title":"Prevalence of mental disorders and impact on quality of life in patients with pulmonary arterial hypertension.","volume":"12","author":"Olsson","year":"2021","journal-title":"Front Psychiatry."},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-014-0451-2","article-title":"Adjustment disorder: new developments.","volume":"16","author":"Casey","year":"2014","journal-title":"Curr Psychiatry Rep."},{"key":"B168","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1007\/BF00172624","article-title":"The prevalence and treatment of depression in general practice.","volume":"95","author":"Blacker","year":"1988","journal-title":"Psychopharmacology."},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0200-2","article-title":"Comorbid depression in medical diseases.","volume":"6","author":"Gold","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B170","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00005053-199601000-00008","article-title":"Prevalence of psychiatric disorders in medical inpatients.","volume":"184","author":"Silverstone","year":"1996","journal-title":"J Nerv Ment Dis."},{"key":"B171","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","article-title":"Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.","volume":"12","author":"Mitchell","year":"2011","journal-title":"Lancet Oncol."},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2020.00143","article-title":"Metacognitive therapy for adjustment disorder in a patient with newly diagnosed pulmonary arterial hypertension: a case report.","volume":"11","author":"Winter","year":"2020","journal-title":"Front Psychol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jts.22295","article-title":"A systematic review of psychological and pharmacological treatments for adjustment disorder in adults.","volume":"31","author":"O\u2019Donnell","year":"2018","journal-title":"J Trauma Stress."},{"key":"B174","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/YCO.0b013e328358e531","article-title":"The third wave of cognitive behavioural therapies: what is new and what is effective?","volume":"25","author":"Kahl","year":"2012","journal-title":"Curr Opin Psychiatry."},{"key":"B175","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1745691618804187","article-title":"A 60-year evolution of cognitive theory and therapy.","volume":"14","author":"Beck","year":"2019","journal-title":"Perspect Psychol Sci."},{"key":"B176","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/PSY.0000000000000626","article-title":"Effectiveness of cognitive behavioral therapy for depression and anxiety in patients with cardiovascular disease: a systematic review and meta-analysis.","volume":"80","author":"Reavell","year":"2018","journal-title":"Psychosom Med."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1017\/S0033291720000598","article-title":"Efficacy of psychological interventions on psychological outcomes in coronary artery disease: systematic review and meta-analysis.","volume":"51","author":"Magan","year":"2021","journal-title":"Psychol Med."},{"key":"B178","year":"2018","journal-title":"Bundes Psychotherapeuten Kammer: Ein Jahr Nach der Reform der Psychotherapie-Richtlinie \u2013 Wartezeiten 2018."},{"key":"B179","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/wps.20151","article-title":"Guided internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis.","volume":"13","author":"Andersson","year":"2014","journal-title":"World Psychiatry."},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.5556","article-title":"The effect of guided web-based cognitive behavioral therapy on patients with depressive symptoms and heart failure: a pilot randomized controlled trial.","volume":"18","author":"Lundgren","year":"2016","journal-title":"J Med Internet Res."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2019.103454","article-title":"The impact of internet-based cognitive behavioral therapy and depressive symptoms on self-care behavior in patients with heart failure: a secondary analysis of a randomised controlled trial.","volume":"116","author":"Johansson","year":"2021","journal-title":"Int J Nurs Stud."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.831359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T01:59:31Z","timestamp":1647395971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.831359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":181,"alternative-id":["10.3389\/fpsyt.2022.831359"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.831359","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"article-number":"831359"}}